Lipoprotein(a) is an LDL-like particle with additional apolipoprotein, apolipoprotein(a), attached to apolipoprotein B.
Apolipoprotein(a) is composed of peptide structures, named kringles, and the greater the repeat numbers of a subtype the structures called kingle IV type 2, the bigger its size
Large apolipoprotein(a) particles remain trapped in the liver and are degraded resulting in low concentrations of lipoprotein(a) in the blood
Evidence exists for an association between raised lipoprotein(a) and high cardiovascular disease risk in the general population.
Lipoprotein(a) is not only cholesterol rich, but has prothrombotic and pro-inflammatory properties.
Cholesterol efflux is mediated predominantly by lipoprotein A1, the main protein in high density lipoproteins (HDL’s).
Patients with impaired cholesterol efflux capacity, have a higher incidence of both short term and long-term death from any cause in patients who have had acute myocardial infarction event.
Zerasiran produces sustained reductions in lipoprotein (a) concentrations.